Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 5 for:    multitaa

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03093350
Recruitment Status : Active, not recruiting
First Posted : March 28, 2017
Results First Posted : April 29, 2020
Last Update Posted : June 4, 2020
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
National Cancer Institute (NCI)
Cancer Prevention Research Institute of Texas
Information provided by (Responsible Party):
Mothaffar Rimawi, Baylor College of Medicine

Brief Summary:

Status - CLOSED TO PATIENT ENROLLMENT (CNPE)

The study is being conducted in patients in which breast cancer has come back after standard treatment. Volunteers in this research study are treated using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.

The proteins that investigators are targeting in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe.

Investigators now want to try this treatment in patients with breast cancer.

These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration.

The purpose of this study is to determine the clinical efficacy of TAA-specific CTLs, to learn what the side-effects are, and to see whether this therapy might help patients with breast cancer.


Condition or disease Intervention/treatment Phase
Breast Cancer Biological: TAA-specific CTLs Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tumor Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Breast Cancer
Actual Study Start Date : October 10, 2017
Actual Primary Completion Date : May 30, 2019
Estimated Study Completion Date : May 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: TAA-Specific CTLs
Patients receiving TAA-specific CTLs as therapy for breast cancer.
Biological: TAA-specific CTLs

Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.

Dose schedule:

Day 0: 2 x 10^7 cells/m2

Day 28: 2 x 10^7 cells/m2

If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.





Primary Outcome Measures :
  1. The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for ≥10 Weeks From the First Infusion (6 Weeks After the Second Infusion) According to the RECIST Criteria [ Time Frame: 12 weeks ]
    To determine the clinical efficacy associated with the administration of multiTAA-specific T cells in breast cancer patients with metastatic or locally recurrent unresectable disease as measured by clinical benefit rate (defined as overall response plus stable disease for 10 weeks or longer). Per the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria and assessed by CT or MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started; Overall Response (OR) = CR + PR.


Secondary Outcome Measures :
  1. Median Progression-free Survival [ Time Frame: 1 year ]
    To evaluate the progression-free survival of patients after multiTAA-specific T cell infusion. Progression is defined, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) Criteria, as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

  2. Median Overall Survival [ Time Frame: 1 year ]
    To evaluate the overall survival of patients after multiTAA-specific T cell infusion



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Status - CLOSED TO PATIENT ENROLLMENT (CNPE)

PROCUREMENT INCLUSION CRITERIA:

  1. Any breast cancer patient with metastatic or locally recurrent unresectable disease.
  2. Patients with life expectancy greater than or equal to 12 weeks.
  3. Age greater than or equal to 18 and less than or equal to 80 years old.
  4. Hgb greater than or equal to 7.0.
  5. Informed Consent explained to, understood by and signed by patient. Patient given copy of informed consent.

TREATMENT INCLUSION CRITERIA:

  1. Any breast cancer patient with metastatic or locally recurrent unresectable breast cancer currently progressive, after at least two prior lines of therapy in the advanced setting. Patients with HER2+ disease must have failed two or more different anti-HER2 agents.
  2. Patients must have measurable or evaluable disease per RECIST 1.1 criteria.
  3. Patients with life expectancy greater than or equal to 12 weeks.
  4. Age greater than or equal to 18 and less than or equal to 80 years old.
  5. Pulse oximetry of greater than 95% on room air.
  6. Patients with ECOG score less than or equal to 2 or a Karnofsky score of greater than or equal to 50.
  7. Patients with bilirubin less than or equal to 2x upper limit of normal, AST less than or equal to 3x upper limit of normal, and Hgb greater than or equal to 7.0.
  8. Patients with a creatinine normal for age.
  9. Patients should have been off other investigational therapy for one month prior to receiving treatment on this study.
  10. Patients should have been off conventional therapy for at least 1 week prior to receiving treatment on this study.
  11. Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion.
  12. Informed Consent explained to, understood by and signed by patient. Patient given copy of informed consent.

PROCUREMENT EXCLUSION CRITERIA:

  1. Patients with severe intercurrent infection.
  2. Patients with active HIV infection at time of procurement.
  3. Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation.

TREATMENT EXCLUSION CRITERIA:

  1. Patients with severe intercurrent infection.
  2. Patients receiving systemic corticosteroids (Patients off steroids for at least 48 hours are eligible).
  3. Pregnant or lactating.
  4. Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation.
  5. HIV positive.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03093350


Locations
Layout table for location information
United States, Texas
Houston Methodist Hospital
Houston, Texas, United States, 77030
Smith Clinic - Harris Health System
Houston, Texas, United States, 77054
Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
National Cancer Institute (NCI)
Cancer Prevention Research Institute of Texas
Investigators
Layout table for investigator information
Principal Investigator: Mothaffar F Rimawi, MD Baylor College of Medicine
Principal Investigator: Anne Leen, PhD Baylor College of Medicine
  Study Documents (Full-Text)

Documents provided by Mothaffar Rimawi, Baylor College of Medicine:
Layout table for additonal information
Responsible Party: Mothaffar Rimawi, Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT03093350    
Other Study ID Numbers: H-39209 TACTIC
P50CA186784 ( U.S. NIH Grant/Contract )
First Posted: March 28, 2017    Key Record Dates
Results First Posted: April 29, 2020
Last Update Posted: June 4, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Mothaffar Rimawi, Baylor College of Medicine:
Breast Cancer
Tumor Associated Antigen Specific T cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases